Live Feeds
● LIVE Updated 21m ago · 12 sources tracked

Seven new tumor cases reported among patients on Novartis’ Zolgensma gene therapy

Novartis confirmed 9 reported cases of tumors in patients treated with its Zolgensma gene therapy, with 7 new cases recently reported. The gene therapy is used to treat spinal muscular atrophy (SMA). The company is investigating the potential link between the therapy and the tumors.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (12)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Novartis confirmed 9 reported cases of tumors in patients treated with Zolgensma
  • ✓ Seven new tumor cases were recently reported among patients on Novartis' Zolgensma gene therapy
  • ✓ Zolgensma is used to treat spinal muscular atrophy (SMA)
🛡️ Source Corroboration: 12 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Novartis confirmed 9 reported cases of tumors in patients treated with Zolgensma, with 7 new cases recently reported, increasing the total number of reported cases.

Live updates

  1. Novartis reports 9 tumor cases in Zolgensma gene therapy patients

    Novartis confirmed 9 reported cases of tumors in patients treated with its Zolgensma gene therapy, with 7 new cases recently reported. The gene therapy is used to treat spinal muscular atrophy (SMA). The company is investigating the potential link between the therapy and the tumors.

    Why it matters

    Zolgensma is a gene therapy treatment for spinal muscular atrophy, a genetic disorder that affects nerve cells responsible for controlling voluntary muscle movement. The treatment uses a viral vector to deliver a functional copy of the SMN1 gene to patients. The reports of tumors in patients who received Zolgensma have raised concerns about the safety of the therapy.

    What is confirmed

    • Novartis confirmed 9 reported cases of tumors in patients treated with Zolgensma
    • Seven new tumor cases were recently reported among patients on Novartis' Zolgensma gene therapy
    • Zolgensma is used to treat spinal muscular atrophy (SMA)

    What to watch next

    • Further investigation into the cause of the tumors and their potential link to Zolgensma
    • Novartis' response to the reports and potential changes to the therapy or its usage
    • Regulatory actions or reviews of Zolgensma's safety and efficacy
    Sources used for this update (13)
    1. www.statnews.com — STAT — Reporting from the frontiers of health and medicine
    2. en.wikipedia.org — Seven (1995 film) - Wikipedia
    3. en.wikipedia.org — 7 - Wikipedia
    4. www.rottentomatoes.com — Seven - Rotten Tomatoes
    5. tubitv.com — Seven (1995) - Stream Free | Tubi
    6. www.primevideo.com — Seven (1995) - Prime Video
    7. BioSpace — Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
    8. Endpoints News — Seven new tumor cases reported among patients on Novartis’ Zolgensma gene therapy
    9. Bloomberg.com — Novartis Says Tumors Found in Children Given SMA Gene Therapy
    10. Muscular Dystrophy Association — Statement from the Muscular Dystrophy Association on Reports of Tumors in People Treated with Zolgensma
    11. STAT — Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
    12. www.devdiscourse.com — Reuters Health News Summary
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community